[go: up one dir, main page]

MX2024004377A - Tratamiento mejorado de la dermatitis atopica con tradipitant. - Google Patents

Tratamiento mejorado de la dermatitis atopica con tradipitant.

Info

Publication number
MX2024004377A
MX2024004377A MX2024004377A MX2024004377A MX2024004377A MX 2024004377 A MX2024004377 A MX 2024004377A MX 2024004377 A MX2024004377 A MX 2024004377A MX 2024004377 A MX2024004377 A MX 2024004377A MX 2024004377 A MX2024004377 A MX 2024004377A
Authority
MX
Mexico
Prior art keywords
tradipitant
atopic dermatitis
improved treatment
treatment
improved
Prior art date
Application number
MX2024004377A
Other languages
English (en)
Inventor
Polymeropoulos Mihael H
Changfu Xiao
Gunther Birznieks
Andrew Heitman
Sandra Smieszek
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2024004377A publication Critical patent/MX2024004377A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La descripción se refiere a métodos mejorados para el tratamiento de la dermatitis atópica y sus síntomas con tradipitant.
MX2024004377A 2017-09-13 2020-03-13 Tratamiento mejorado de la dermatitis atopica con tradipitant. MX2024004377A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762558303P 2017-09-13 2017-09-13
US201762572456P 2017-10-14 2017-10-14

Publications (1)

Publication Number Publication Date
MX2024004377A true MX2024004377A (es) 2024-04-26

Family

ID=63684468

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002852A MX2020002852A (es) 2017-09-13 2018-08-30 Tratamiento mejorado de dermatitis atopica con tradipitant.
MX2024004377A MX2024004377A (es) 2017-09-13 2020-03-13 Tratamiento mejorado de la dermatitis atopica con tradipitant.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020002852A MX2020002852A (es) 2017-09-13 2018-08-30 Tratamiento mejorado de dermatitis atopica con tradipitant.

Country Status (11)

Country Link
US (1) US11549147B2 (es)
EP (2) EP3681505B1 (es)
JP (1) JP7347743B2 (es)
KR (2) KR20200054232A (es)
CN (1) CN111093671A (es)
AU (1) AU2018331267B2 (es)
CA (1) CA3073998A1 (es)
CL (1) CL2020000655A1 (es)
IL (1) IL272949B2 (es)
MX (2) MX2020002852A (es)
WO (1) WO2019055225A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385788B (es) * 2015-03-04 2025-03-18 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant.
JP7410137B2 (ja) 2018-06-08 2024-01-09 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントを用いる処置方法
AU2021227900A1 (en) * 2020-02-25 2022-09-15 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
EP4125811A1 (en) 2020-03-26 2023-02-08 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
EP3996169B1 (en) 2020-05-07 2025-02-26 LG Energy Solution, Ltd. High-nickel electrode sheet and method for manufacturing same
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
EP4637766A1 (en) 2022-12-21 2025-10-29 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263498B (es) 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
PT1501809E (pt) 2002-04-26 2008-03-18 Lilly Co Eli Derivados de triazole como antagonistas de receptores de taquiquinina
DK1501808T3 (da) 2002-04-26 2008-10-13 Lilly Co Eli Tachykininreceptor-antagonister
JP2004250329A (ja) * 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EA008881B1 (ru) 2003-10-24 2007-08-31 Эли Лилли Энд Компани Новые кристаллические формы {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1h-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Ｔｈ１型アレルギー疾患治療用組成物
DE102005006217B4 (de) * 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
CA2643130A1 (en) 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compounds and methods of treating disorders associated with activation of metachromatic cells
DK2121610T3 (da) 2006-12-20 2014-06-30 Lilly Co Eli Hidtil ukendt mellemprodukt og fremgangsmåde, som er anvendelige ved fremstilling af {2-[1-(3,5-bis-trifluormethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorphenyl)-methanon
JP6644328B2 (ja) * 2013-02-28 2020-02-12 ロート製薬株式会社 アトピー性疾患の発症又は重症化リスクの評価法
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
CN105473138A (zh) * 2013-06-24 2016-04-06 虎猫制药公司 Nk-1受体拮抗剂司洛匹坦在瘙痒中的用途
MX385788B (es) 2015-03-04 2025-03-18 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant.
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness

Also Published As

Publication number Publication date
KR20250036264A (ko) 2025-03-13
MX2020002852A (es) 2020-07-22
AU2018331267A1 (en) 2020-04-16
US20210062262A1 (en) 2021-03-04
CN111093671A (zh) 2020-05-01
WO2019055225A1 (en) 2019-03-21
EP3681505C0 (en) 2024-12-18
BR112020004964A2 (pt) 2020-09-15
US11549147B2 (en) 2023-01-10
EP4487912A3 (en) 2025-03-26
CL2020000655A1 (es) 2020-10-09
RU2020112222A (ru) 2021-10-13
JP7347743B2 (ja) 2023-09-20
IL272949A (en) 2020-04-30
EP4487912A2 (en) 2025-01-08
EP3681505B1 (en) 2024-12-18
EP3681505A1 (en) 2020-07-22
JP2020533381A (ja) 2020-11-19
IL272949B1 (en) 2025-03-01
IL272949B2 (en) 2025-07-01
KR20200054232A (ko) 2020-05-19
AU2018331267B2 (en) 2024-03-07
CA3073998A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
MX2024004377A (es) Tratamiento mejorado de la dermatitis atopica con tradipitant.
CY1123065T1 (el) Ανασυνδυασμενα προβιοτικα βακτηριδια
MX389468B (es) Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña
MX2021010460A (es) Metodo de tratamiento con tradipitant.
TWD174683S (zh) 戒指
GEAP201914237A (en) Heteroaryls and uses thereof
GEAP202114450A (en) Anti-tigit antibodies
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
MX373818B (es) Composiciones de apilimod y métodos para usar las mismas.
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX395060B (es) Sistemas y métodos de control adecuados para el uso con sistemas y métodos de producción de energía.
TWD171584S (zh) 自動出入閘門
MX2018007123A (es) Control remoto para el control de aparatos mediante la desviacion de la señal de realimentacion del control nativo al control remoto y metodos para el mismo.
AR106133A1 (es) Métodos para el tratamiento de la epilepsia
PL3446187T3 (pl) Sposób eksploatacji instalacji wytwórczej i instalacja wytwórcza
MX386150B (es) Tasimelteon para tratar el síndrome de smith-magenis.
MX2016016664A (es) Metodos para tratar condiciones con anticuerpos que enlazan al receptor de factor 1 estimulador de colonias (csf1r).
CL2016000672A1 (es) Bacteria aislada del género streptomyces
MX2019002673A (es) Composiciones y metodos para tratar demencia.
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
MX385652B (es) Composicion heterofasica.
TWD179337S (zh) 管配件
TWD180363S (zh) 水龍頭
MX376367B (es) Activacion del factor x.